A hammer to crack a nut, is it nuts to think that immunosupressives do not cause PML

Van Schependom J, Gielen J, Laton J, Nagels G. Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail. Mult Scler. 2015 pii: 1352458515596458. [Epub ahead of print]
Recently, three progressive multifocal leukoencephalopathy (PML) cases have been reported in multiple sclerosis (MS) patients, two treated with fingolimod (Gilenya, Novartis), the third with dimethyl fumarate (Tecfidera, Biogen). Because our immunotherapeutic arsenal in MS and other diseases is increasing, and because PML is a very serious health risk, it is of interest to the clinical community to show how we can assess this risk in a statistically sound way. The null-hypothesis for this analysis was that there is no elevated risk for PML in patients treated with one of these recent drugs, compared to the incidence in the general population. We conclude that the null hypothesis cannot be refuted.

So this stuff says they think that some oral DMT that are generalised immunosuppressives do not cause PML. Wake up an smell the roses people. Long term leucopeania caused by such drugs is going to leave you at risk of infection. It may not be a high risk but it is a risk.

Labels: ,